Oncolines® Technology Platforms for Precision Oncology
Cell-Based Assays to Determine Genetic Drivers and Biological Pathways for Precision Oncology
Oncolines® Cancer Cell Lines, Proliferation Assays and Bioinformatics Analysis
SynergyFinder™ Screen for Synergistic Drug and Therapy Combinations
- Determination of synergy for combination therapy by curve-shift analysis and CI values
- Reference dataset of >180 compounds available
- Hypothesis driven experiments as well as broad screening
Mechanistic Cell Biology, In Vitro Assays to Determine Mechanism of Action
- Flexible assay development and screening,
- Proof of concept studies, determination of mechanism of action
- Testing of a wide range of cancer cells, immune cells and primary patient material in vitro
Customized Bioinformatics Analyses
- Analyses tailored to specific project needs
- Derivation of meaningful insights from complex biological data
ResidenceTimer™ Surface Plasmon Resonance (SPR) Platform for Kinetic Binding Experiments
- Measures target residence time and on- and off-rates
- Provides a mechanistic rationale for the distinct pharmacological features of one drug candidate compared to another
Biochemical Assays for Drug–Target Interactions
- Selection of the best drug candidate for your target via a variety of assays
- Proof of concept studies, determination of molecular interactions
- Kinase panel screening for rapid and accurate determination of selectivity
Efficient, Convenient, Secure Reporting
- Primary data and final reports shared via a secured link
Continuous and High-Throughput Screening
- Turnaround time starts at day of arrival of compounds at Oncolines and ends with transfer of final report and primary data
Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster
Oncolines offers a set of complimentary technologies to enable clients to determine the activity, selectivity and mechanism of action of drugs and drug candidates
- Available on a fee-for-service basis and collaborations via an integrated precision medicine approach.
It is our mission to bring improved and novel therapies to the right patient population faster.